PharmAbcine Inc. is a bio venture specialized in R&D of antibody treatment in the clinical stage and currently possesses core technologies such as potent antibody development technology using potent non-immune scFv phage display library, new-generation double target antibody production technology, and antibody production technology using cancer stem cell library. Since we were established in 2008 we have been devoted to developing new cancer antibody drugs and laying a foundation for TTAC-0001 and PMC-001. We will constantly develop pipelines for sustainable growth with a vision to release a new global blockbuster bio drug by 2020 and become a global bioengineering company.
◑ Core Technology Potent antibody development technology using potent non-immune scFv phage display library,
◑ Double target antibody production technology
◑ Antibody evaluation technology using patients' cancer stem cell library
◑ ADC-based antibody therapy development technology
◑ Immune anti-cancer antibody drug development technology
◑ Cell treatment development technology based on CAR-T/NK